Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 34812950.
- Also identified by DOI 10.1007/s00701-021-05061-1 and PMC identifier 8609840.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
H3K27M-mutant diffuse midline glioma (H3K27M-mt DMG) was a novel entity, which was defined by K27M mutations in H3F3A or HIST1H3B/C in the 2016 WHO updated fourth edition of the central nervous system (CNS) tumor classification. There is an urgent need for effective therapeutic strategies. Anlotinib is a multitarget tyrosine kinase inhibitor, which has not been reported for H3K27M-mt DMG treatment. Here, we firstly reported an adult multifocal H3K27M-mt DMG patient benefiting from anlotinib. This report provides a promising treatment option for H3K27M-mt DMG patients.
Medical subject headings
- Adult
- Brain Neoplasms
- Brain Neoplasms/drug therapy
- Brain Neoplasms/genetics
- Glioma
- Glioma/drug therapy
- Glioma/genetics
- Histones
- Histones/genetics
- Humans
- Indoles
- Indoles/therapeutic use
- Molecular Targeted Therapy
- Mutation
- Protein-Tyrosine Kinases
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Quinolines
- Quinolines/therapeutic use
- Receptor, Platelet-Derived Growth Factor alpha
- Receptor, Platelet-Derived Growth Factor alpha/genetics